D70
Conditions
Interventions
Group 1: Data will be gathered by studying available paper-based documentation like doctor’s letters, medical reports and lab reports. Only patients with Autoimmune neutropenia (AIN) will be offered a
Sponsors
Universitätsklinikum Freiburg
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Informed consent Diagnosis of AIN at least one follow-up visit in our Department of Pediatric Hematology and Oncology Diagnosis of reactive neutropenia, severe congenital neutropenia, alloimmune neutropenia, cyclic neutropenia
Exclusion criteria
Exclusion criteria: Absence of informed consent Neutropenia due to treatment of malignant disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoint will be to characterize a large cohort of patients with AIN regarding the diagnostic approach compared to existing guidelines and the progression of the disease with focus on the long-term course and evaluation of late effects or complications. | — |
Secondary
| Measure | Time frame |
|---|---|
| Several secondary endpoints including lab parameters, individual duration of neutropenia, number of hospitalizations, frequency of infections, medical history after diagnosis of AIN, and impact of disease on the family’s psychosocial situation will be assessed, as well. | — |
Countries
Germany
Contacts
Public ContactAlexander Puzik
Universitätsklinikum Freiburg
Outcome results
None listed